EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Home
/
update
/
details

Qure.ai Earns 12th Indian Patent for Advanced Lung Abnormality Detection System

NextEdge Admin

14 Aug 2024

2 min 8 sec

Mumbai-based healthcare AI leader Qure.ai has secured its 12th Indian patent for a system and method to detect lung abnormalities in medical images. This patent, awarded by the Indian Patent Office, marks Qure.ai’s first achievement involving a large language model (LLM) in medical imaging and AI. With this addition, the company’s global patent portfolio now includes 29 patents.

Qure.ai’s patented system integrates imaging AI with LLM models, enabling the combination of image analysis and patient data for precise diagnoses. The system provides an abnormality confidence score, enhancing diagnostic reliability. It is designed to track lung abnormalities over time, supporting disease progression monitoring and aiding in treatment planning. Notably, the self-evolving model continually updates with each new input, reflecting the latest medical knowledge. It is built for scalability, accommodating new medical data and imaging techniques, and can seamlessly integrate with hospital information systems and electronic health records (EHRs).

With operations in over 90 countries and more than 2,700 sites, Qure.ai has impacted over 20 million lives globally. The company’s diverse patent portfolio includes innovations in advanced image analysis, pattern recognition, workflow optimization, decision support systems, and quality assurance in healthcare AI. This latest patent further solidifies Qure.ai’s position as a global leader in healthcare AI, showcasing its commitment to advancing medical imaging and improving patient outcomes.